Cubist Reaches New 52-Week High (CBST)

NEW YORK (TheStreet) -- Cubist Pharmaceuticals (Nasdaq:CBST) hit a new 52-week high Wednesday as it is currently trading at $42.50, above its previous 52-week high of $42.39 with 737,797 shares traded as of 3:15 p.m. ET. Average volume has been 798,900 shares over the past 30 days.

Cubist has a market cap of $2.41 billion and is part of the health care sector and drugs industry. Shares are up 5.6% year to date as of the close of trading on Tuesday.

Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company has a P/E ratio of 15.5, below the average drugs industry P/E ratio of 75.2 and below the S&P 500 P/E ratio of 17.7.

• Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Cubist as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. You can view the full Cubist Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

For more information on Cubist Pharmaceuticals Inc. click any of the following:

• Cubist Pharmaceuticals Inc. Stock Price

• Cubist Pharmaceuticals Inc. Analyst Ratings

• Cubist Pharmaceuticals Inc. Key Stats & Profile

• Cubist Pharmaceuticals Inc. Earnings

• Cubist Pharmaceuticals Inc. Ratio Comparison

• Cubist Pharmaceuticals Inc. Growth Rates

• Cubist Pharmaceuticals Inc. Balance Sheet

• Cubist Pharmaceuticals Inc. Cash Flow

• Cubist Pharmaceuticals Inc. Income Statement